Overview
- Editors:
-
-
Godefridus J. Peters
-
VU University Medical Center Amsterdam, The Netherlands
Access this book
Other ways to access
Table of contents (17 chapters)
-
Front Matter
Pages i-xiii
-
- Marçal Pastor-Anglada, F. Javier Casado
Pages 1-28
-
- Maria Staub, Staffan Eriksson
Pages 29-52
-
- Birgitte Munch-Petersen, Jure Piškur
Pages 53-79
-
- Sally Anne Hunsucker, Beverly S. Mitchell, Jozef Spychala
Pages 81-108
-
- Piet Borst, Peter Wielinga
Pages 109-117
-
- Isabelle Hubeek, Gert-Jan L. Kaspers, Gert J. Ossenkoppele, Godefridus J. Peters
Pages 119-152
-
- Varsha Gandhi, William Plunkett
Pages 153-171
-
- Giuseppe Gumina, Youhoon Chong, Chung K. Chu
Pages 173-198
-
- Henriette Gourdeau, Jacques Jolivet
Pages 199-214
-
- Sophie Curbo, Anna Karlsson
Pages 215-224
-
- Andries M. Bergman, Godefridus J. Peters
Pages 225-251
-
- Judith R. Kroep, Godefridus J. Peters, Robert A. Nagourney
Pages 253-288
-
- Donna S. Shewach, Theodore S. Lawrence
Pages 289-329
-
-
- Chris Meier, Jan Balzarini, Astrid Meerbach
Pages 353-401
-
- Zoran Gojkovic, Anna Karlsson
Pages 403-439
-
- Wieteke G. E. Direcks, Adriaan A. Lammertsma, Carla F. M. Molthoff
Pages 441-462
-
Back Matter
Pages 463-476
About this book
Successful cancer chemotherapy relies heavily on the application of various deoxynucleoside analogs. Since the very beginning of modern cancer chemotherapy, a number of antimetabolites have been introduced into the clinic and subsequently applied widely for the treatment of many malignancies, both solid tumors and hematological disorders. In the latter diseases, cytarabine has been the mainstay of treatment of acute myeloid leukemia. Although many novel compounds were synthesized in the 1980s and 1990s, no real improvement was made. However, novel technology is now capable of elucidating the molecular basis of several inborn errors as well as some specific malignancies. This has enabled the synthesis of several deoxynucleoside analogs that could be applied for specific malignancies, such as pentostatin and subsequently chlorodeoxyadenosine (cladribine) for the treatment of hairy cell leukemia. Already in the early stage of deoxynucleoside analog development, it was recognized that several of these compounds were very effective in the treatment of various viral infections, such as for the treatment of herpes infections. This formed the basis initially for the design of azidothymidine and subsequently many other analogs, which are currently successfully used for the treatment of HIV infections. As a spin-off of these research lines, some compounds not eligible for development as antiviral agents appeared to be very potent anticancer agents. The classical example is gemcitabine, now one of the most widely applied deoxynucleoside analogs, used for the (combination) treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer, and ovarian cancer.
Reviews
"...a top-notch overview of the current knowledge in the area of deoxynucleoside analog development and application in the treatment of cancer." -Weighted Numerical Score: 92 - 4 Stars!-Doody's Health Science Book Review Journal
"...an excellent book that is suitable for researchers or clinicians with an interest in deoxynucleoside analgos and/or cancer chemotherapy." -Weighted Numerical Score: 92 - 4 Stars!-Doody's Health Science Book Review Journal
Editors and Affiliations
-
VU University Medical Center Amsterdam, The Netherlands
Godefridus J. Peters
